Literature DB >> 10832745

Immunophenotypic changes of fetal cord blood hematopoietic progenitor cells during gestation.

A Gasparoni1, L Ciardelli, M A Avanzini, M Bonfichi, M di Mario, G Piazzi, L Martinotti, L Vanelli, G Rondini, G Chirico.   

Abstract

We measured cell surface expression of CD34, HLA-DR, CD38, CD19, CD33, CD71, and CD45 antigens in the hematopoietic progenitor cells of fetal cord blood to investigate immunophenotypic changes at different gestational ages. These antigens were identified by flow cytometry in 11 fetuses (gestational age 19-24 wk, in 12 preterm (25-28 wk) and in ten newborn infants born at term. The frequency and number of CD34+ cells were higher in the blood of the 11 fetuses; in addition, a statistically significant inverse correlation between number of CD34+ cells and advancing gestational age was noted. The numbers of CD34+ CD19+, CD34+ CD33+, and CD34+ CD45+ coexpressing cells were significantly higher in the fetuses, whereas CD34+ CD38+ cells were more represented in the neonates at term. Gestational age was inversely correlated with the number of CD34+ CD19+ and CD34+ CD33+ coexpressing cells. A positive correlation between gestational age and CD34+ CD38+ cells was noted. The number of CD34- CD19+, CD34- CD38+, and CD34- CD45+ cells was higher in term infants; furthermore, a significant correlation between advancing gestational age and CD34- CD38+ or CD34- CD45+ cells was demonstrated. The proliferative capacity was also higher at lower gestational ages. These data suggest that the development and lineage commitment of fetal cord blood hematopoietic progenitor cells are very active during the last two trimesters of pregnancy. The most significant changes of hematopoietic cells maturation seem to occur within 25 wk of gestation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10832745     DOI: 10.1203/00006450-200006000-00024

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  4 in total

1.  Term vs. preterm cord blood cells for the prevention of preterm brain injury.

Authors:  Jingang Li; Tamara Yawno; Amy Sutherland; Jan Loose; Ilias Nitsos; Beth J Allison; Robert Bischof; Courtney A McDonald; Graham Jenkin; Suzanne L Miller
Journal:  Pediatr Res       Date:  2017-08-16       Impact factor: 3.756

2.  Optimizing donor selection for public cord blood banking: influence of maternal, infant, and collection characteristics on cord blood unit quality.

Authors:  Kristin M Page; Adam Mendizabal; Brigid Betz-Stablein; Stephen Wease; Kevin Shoulars; Tracy Gentry; Vinod K Prasad; Jessica Sun; Shelly Carter; Andrew E Balber; Joanne Kurtzberg
Journal:  Transfusion       Date:  2013-05-27       Impact factor: 3.157

Review 3.  Could cord blood cell therapy reduce preterm brain injury?

Authors:  Jingang Li; Courtney A McDonald; Michael C Fahey; Graham Jenkin; Suzanne L Miller
Journal:  Front Neurol       Date:  2014-10-09       Impact factor: 4.003

4.  Hematopoietic stem cells in neonates: any differences between very preterm and term neonates?

Authors:  Lukas Wisgrill; Simone Schüller; Markus Bammer; Angelika Berger; Arnold Pollak; Teja Falk Radke; Gesine Kögler; Andreas Spittler; Hanns Helmer; Peter Husslein; Ludwig Gortner
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.